A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Conditions

• Obesity

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• NNC0662-0419 — DRUG
  NNC0662-0419 will be administered subcutaneously.
• Semaglutide — DRUG
  Semaglutide will be administered subcutaneously.
• NNC0662-0419 Placebo — DRUG
  Placebo matched to NNC0662-0419 will be administered subcutaneously.
• Semaglutide placebo — DRUG
  Placebo matched to semaglutide will be administered subcutaneously.

Study Details

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Key Dates

First listed

Jun 10, 2026

Start date

Jun 9, 2026

Status verified

Jul 2026

Primary completion

Jul 12, 2027

Completion

Jul 12, 2027

Study Design

Enrollment

230 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: NNC0662-0419
  Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner.
• Placebo Comparator: NNC0662-0419 placebo
  Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner.
• Experimental: Semaglutide
  Participants will receive semaglutide administered subcutaneously in a dose-escalation manner.
• Placebo Comparator: Semaglutide placebo
  Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner.

Primary Outcome Measure

Number of gastrointestinal adverse events [ Time Frame: From week 0 to week 39 ]

Central Contacts

• Novo Nordisk
  (+1) 866-867-7178
  [email protected]

Locations (24)

Find similar trials in Montgomery, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
• New Heart Imaging Techniques to Evaluate Possible Heart Disease
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland